These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 26883274)

  • 1. MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival.
    Radoul M; Chaumeil MM; Eriksson P; Wang AS; Phillips JJ; Ronen SM
    Mol Cancer Ther; 2016 May; 15(5):1113-22. PubMed ID: 26883274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide.
    Prasad G; Sottero T; Yang X; Mueller S; James CD; Weiss WA; Polley MY; Ozawa T; Berger MS; Aftab DT; Prados MD; Haas-Kogan DA
    Neuro Oncol; 2011 Apr; 13(4):384-92. PubMed ID: 21317208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma.
    Venkatesh HS; Chaumeil MM; Ward CS; Haas-Kogan DA; James CD; Ronen SM
    Neuro Oncol; 2012 Mar; 14(3):315-25. PubMed ID: 22156546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperpolarized 13C MR spectroscopic imaging can be used to monitor Everolimus treatment in vivo in an orthotopic rodent model of glioblastoma.
    Chaumeil MM; Ozawa T; Park I; Scott K; James CD; Nelson SJ; Ronen SM
    Neuroimage; 2012 Jan; 59(1):193-201. PubMed ID: 21807103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
    Wu Y; Dong L; Bao S; Wang M; Yun Y; Zhu R
    Biomed Pharmacother; 2016 Dec; 84():462-469. PubMed ID: 27685789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development.
    Zhao HF; Wang J; Shao W; Wu CP; Chen ZP; To ST; Li WP
    Mol Cancer; 2017 Jun; 16(1):100. PubMed ID: 28592260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.
    Wen PY; Omuro A; Ahluwalia MS; Fathallah-Shaykh HM; Mohile N; Lager JJ; Laird AD; Tang J; Jiang J; Egile C; Cloughesy TF
    Neuro Oncol; 2015 Sep; 17(9):1275-83. PubMed ID: 26019185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases.
    Choi EJ; Cho BJ; Lee DJ; Hwang YH; Chun SH; Kim HH; Kim IA
    BMC Cancer; 2014 Jan; 14():17. PubMed ID: 24418474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma.
    Gil del Alcazar CR; Hardebeck MC; Mukherjee B; Tomimatsu N; Gao X; Yan J; Xie XJ; Bachoo R; Li L; Habib AA; Burma S
    Clin Cancer Res; 2014 Mar; 20(5):1235-48. PubMed ID: 24366691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice.
    Dai C; Zhang B; Liu X; Ma S; Yang Y; Yao Y; Feng M; Bao X; Li G; Wang J; Guo K; Ma W; Xing B; Lian W; Xiao J; Cai F; Zhang H; Wang R
    Endocrinology; 2013 Mar; 154(3):1247-59. PubMed ID: 23384836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma.
    Wu S; Wang S; Zheng S; Verhaak R; Koul D; Yung WK
    Mol Cancer Ther; 2016 Jul; 15(7):1656-68. PubMed ID: 27196759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy.
    Ströbele S; Schneider M; Schneele L; Siegelin MD; Nonnenmacher L; Zhou S; Karpel-Massler G; Westhoff MA; Halatsch ME; Debatin KM
    PLoS One; 2015; 10(6):e0131670. PubMed ID: 26121251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resveratrol enhances the antitumor effects of temozolomide in glioblastoma via ROS-dependent AMPK-TSC-mTOR signaling pathway.
    Yuan Y; Xue X; Guo RB; Sun XL; Hu G
    CNS Neurosci Ther; 2012 Jul; 18(7):536-46. PubMed ID: 22530672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring.
    Chaumeil MM; Radoul M; Najac C; Eriksson P; Viswanath P; Blough MD; Chesnelong C; Luchman HA; Cairncross JG; Ronen SM
    Neuroimage Clin; 2016; 12():180-9. PubMed ID: 27437179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival.
    Batsios G; Viswanath P; Subramani E; Najac C; Gillespie AM; Santos RD; Molloy AR; Pieper RO; Ronen SM
    Sci Rep; 2019 Jul; 9(1):10521. PubMed ID: 31324855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in pyruvate metabolism detected by magnetic resonance imaging are linked to DNA damage and serve as a sensor of temozolomide response in glioblastoma cells.
    Park I; Mukherjee J; Ito M; Chaumeil MM; Jalbert LE; Gaensler K; Ronen SM; Nelson SJ; Pieper RO
    Cancer Res; 2014 Dec; 74(23):7115-24. PubMed ID: 25320009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pediatric and adult glioblastoma radiosensitization induced by PI3K/mTOR inhibition causes early metabolic alterations detected by nuclear magnetic resonance spectroscopy.
    Agliano A; Balarajah G; Ciobota DM; Sidhu J; Clarke PA; Jones C; Workman P; Leach MO; Al-Saffar NMS
    Oncotarget; 2017 Jul; 8(29):47969-47983. PubMed ID: 28624789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells.
    Al-Saffar NMS; Agliano A; Marshall LV; Jackson LE; Balarajah G; Sidhu J; Clarke PA; Jones C; Workman P; Pearson ADJ; Leach MO
    PLoS One; 2017; 12(7):e0180263. PubMed ID: 28704425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.